

Title (en)

QUINAZOLINE DERIVATIVES AS MODULATORS OF MUTANT KRAS, HRAS OR NRAS

Title (de)

CHINAZOLINDERIVATE ALS MODULATOREN VON MUTANTEN KRAS, HRAS ODER NRAS

Title (fr)

DÉRIVÉS DE QUINAZOLINE UTILISÉS EN TANT QUE MODULATEURS DE KRAS, HRAS OU NRAS MUTANTS

Publication

**EP 3630747 A1 20200408 (EN)**

Application

**EP 18731661 A 20180524**

Priority

- US 201762511152 P 20170525
- US 2018034470 W 20180524

Abstract (en)

[origin: WO2018218069A1] Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5, L1, L2, E, m1 and m2 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

IPC 8 full level

**A61K 31/517** (2006.01); **A61P 35/00** (2006.01); **C07D 403/04** (2006.01); **C07D 403/14** (2006.01)

CPC (source: EP US)

**A61P 35/00** (2017.12 - EP); **C07D 403/04** (2013.01 - EP US); **C07D 403/14** (2013.01 - EP US); **C07B 2200/07** (2013.01 - US)

Citation (search report)

See references of WO 2018218069A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

**WO 2018218069 A1 20181129**; CN 110831933 A 20200221; EP 3630747 A1 20200408; JP 2020521740 A 20200727; US 11639346 B2 20230502; US 2020115363 A1 20200416

DOCDB simple family (application)

**US 2018034470 W 20180524**; CN 201880034310 A 20180524; EP 18731661 A 20180524; JP 2019564453 A 20180524; US 201816616066 A 20180524